Kids’ Panadol off the shelf
June 7, 2013
THE Federal Court has granted
Reckitt Benckiser an injunction
which restrains GlaxoSmithKline
from marketing and selling
its Children’s Panadol 1-5
years product, pending a final
determination of the matter.
The ruling applies to Children’s
Panadol 1-5 years, of any flavour
or size, “incorporating a liquid
dispensing apparatus, comprising a
bottle, a bottle neck liner and a flatnosed
syringe,” according to orders
issued by the court last week.
Reckitt Benckiser says the dosing
system on the Children’s Panadol
product is an infringement of the
patent for the system used on its
Nurofen for Children range.
The company said the decision
recognises “the leadership shown
by Nurofen for Children with its
patented innovative dosing system.
“As the fastest growing brand
in the children’s analgesics
market, Nurofen for Children has
increasingly delivered to the needs
of Australian mums and children
since the 1990s,” Reckitt Benckiser
added.
The injunction restrains GSK
from “making, hiring, selling or
otherwise disposing of, or offering
to make, sell hire or otherwise
dispose of, use or import or keep
for the purpose of doing any of the
foregoing, the Children’s Panadol
product.
The next stage of the proceedings
is a directions hearing, which is set
down for 9.30am next Fri morning.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 13
